Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica
Rheumatic Disease Clinics of North America · 2024-05 · 50 (2) · 255-267
DOI: 10.1016/j.rdc.2024.02.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rheumatic Disease Clinics of North America, 2024-05. Verfasst von David F L Liew und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Austin Health, Heidelberg West VIC 3081, Australia; Department of Clinical Pharmacology and Therapeutics, Austin Health, …. Hauptthemen laut MEDLINE: Polymyalgia Rheumatica, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMRs) represent a novel, distinct entity, despite many clinical, laboratory, and imaging similarities to classical PMR. Important questions remain in differentiating ICI-PMR from classical PMR, as well as other immune-related adverse events and PMR mimics. Despite this, ICI-PMR currently takes treatment cues from classical PMR, albeit with considerations relevant to cancer immunotherapy. Comparisons between ICI-PMR and classical PMR may provide further bidirectional insights, especially given that important questions remain unanswered about both diseases. The cause of classical PMR remains poorly understood, and ICI-PMR may represent a model of induced PMR, with important therapeutic implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Austin Health, Heidelberg West VIC 3081, Australia; Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg VIC 3084, Australia; Department of Medicine, University of…
- Division of Rheumatic and Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Worsley Buil…
- LBAI UMR1227, Univ Brest, Inserm, Brest, France; Department of Rheumatology, CHU Brest, France Boulevard TANGUY PRIGENT, Brest, Brittany 29609, France.
- Division of Rheumatology and Clinical Immunology, University of Pittsburgh, BST S723, 3500 Terrace Street, Pittsburgh, PA 15261, USA.
- Norwich Medical School, University of East Anglia, Norwich, UK; Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich, UK.
- Department of Rheumatology, Austin Health, Heidelberg West VIC 3081, Australia; Department of Medicine, University of Melbourne, Parkville, Victoria 3052, Australia.
Zitieren
APA
Liew, D. F. L., Mackie, S. L., Tison, A., Sattui, S. E., Yates, M., Buchanan, R. R. C., & Owen, C. E. (2024). Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica. Rheumatic Disease Clinics of North America, 50(2), 255-267. https://doi.org/10.1016/j.rdc.2024.02.001
Vancouver
Liew DFL, Mackie SL, Tison A, Sattui SE, Yates M, Buchanan RRC, et al. Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica. Rheumatic Disease Clinics of North America. 2024;50(2):255-267. doi:10.1016/j.rdc.2024.02.001
BibTeX
@article{Liew2024,
author = {Liew, David F L and Mackie, Sarah L and Tison, Alice and Sattui, Sebastian E and Yates, Max and Buchanan, Russell R C and Owen, Claire E},
title = {Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica},
journal = {Rheumatic Disease Clinics of North America},
year = {2024},
volume = {50},
number = {2},
pages = {255--267},
doi = {10.1016/j.rdc.2024.02.001}
}
EUVIMED